Probiotics in Newborns: Benefits and Safety

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Probiotics in newborns only make sense when you name the exact strain, the exact CFU dose per day, and the exact population being treated. A meta-analysis of 30 randomized trials found that multi-strain products containing Lactobacillus and Bifidobacterium species reduced the incidence of necrotizing enterocolitis (NEC) in preterm and very low birth weight infants, but the same group of studies shows that the benefit depends on strain, dose, and duration, not on the word "probiotic" on a label [1].

That distinction matters more in newborns than in any other age group. A preterm infant in a neonatal intensive care unit (NICU) and a healthy 3-month-old at home are not the same patient. The evidence for one does not transfer to the other. This article separates the preterm NEC data from the term-infant colic and breastfeeding-colonization claims, gives strain names and doses where trials report them, and covers the 2023 US safety event that changed how many NICUs use these products.

This article is educational and is not a substitute for veterinary diagnosis or treatment.

Why Newborn Gut Colonization Matters

A newborn gut starts nearly sterile and is colonized within hours of birth. The pattern of that colonization shapes immune development, barrier function, and metabolic programming for years. In preterm infants, colonization is disrupted by cesarean delivery, antibiotics, delayed feeding, and immature mucosal immunity. The result is dysbiosis, a microbial community dominated by potentially pathogenic Enterobacteriaceae rather than protective Bifidobacterium and Lactobacillus species [2].

Dysbiosis is one of the pillars of NEC pathogenesis. NEC develops where intestinal immaturity, impaired mucosal immunity, gut dysbiosis, and suboptimal nutrition intersect. Breast milk is protective because it delivers human milk oligosaccharides, lactoferrin, and immunoglobulins that promote intestinal maturation and inhibit pathogen colonization [3]. Probiotics are intended to complement that protection by seeding beneficial bacteria, strengthening the epithelial barrier, and modulating inflammatory signaling [4].

The mechanistic case is strong. The clinical case is strain-specific. Bifidobacterium and Lactobacillus species dominate the research literature, and the effect is larger for NEC prevention than for sepsis prevention [5]. A retrospective cohort of 174 preterm infants found that infants who developed NEC had significantly lower gut microbial diversity at 14 days of life and lower relative abundance of Bifidobacterium and Lactobacillus, compared with controls [2]. That is an association, not proof that supplementation reverses the risk. Only randomized trials can establish causation, and those trials disagree depending on strain.

The Strain and Dose Table

The single most useful thing a clinician or parent can do is stop treating "probiotics" as a category. The table below summarizes the strain-specific evidence discussed in this article. Doses are given exactly as reported in the cited trials. Where a trial did not report a precise CFU dose, that is noted rather than estimated.

The table reveals a pattern that is uncomfortable for product marketers. Several of the most commonly sold formulations do not have published CFU doses in their trial abstracts, and the largest single-strain trial, LGG at 236 infants, failed to show a benefit for its composite outcome [6]. The strongest dose-controlled data come from the L. fermentum plus B. breve trial, which found that the low dose (1 × 10⁶ CFU per strain per day) performed as well as the high dose (1 × 10⁹) for NEC and mortality [8]. That finding supports a lower-dose approach for that specific combination, and it should not be extrapolated to other strains.

Preterm NEC: Where the Evidence Is Strongest

NEC is a devastating gastrointestinal emergency. It affects preterm and low birth weight infants disproportionately, and its incidence is rising in high-income countries as extremely preterm survival improves [3]. Prevention is the priority because treatment options are limited.

Multi-Strain Formulations

Multi-strain probiotic supplementation consistently reduces NEC incidence in meta-analyses. A 2025 systematic review found that multi-strain products reduced NEC, improved feeding tolerance, accelerated full oral feeding, and shortened hospitalization. Selected products also lowered C-reactive protein [1]. The benefit is not uniform across all multi-strain products, and the review noted that strain-specific efficacy varies [1].

The largest dose-finding trial tested L. fermentum CECT5716 and B. breve CECT7263, both isolated from human milk, in 583 very low birth weight preterm neonates. NEC occurred in 2.5% of the high-dose group and 1.3% of the low-dose group, a difference that was not significant. Mortality was 3.9% versus 3.6%. Both rates were lower than a co-temporal regional cohort, which suggests the low dose may be sufficient for preterm infants of this gestational age [8].

A separate retrospective cohort in the Netherlands evaluated a formulation of B. infantis Bb-02, B. lactis BB-12, and S. thermophilus TH-4 introduced as routine care in two NICUs [9]. That study is observational, not randomized, so it cannot establish causation, but it adds real-world data on implementation.

The follow-up data are reassuring on neurodevelopment. The SiMPro trial followed extremely preterm infants for five years after receiving either a single strain (B. breve M-16V) or a triple-strain combination (B. breve M-16V plus B. longum subsp. infantis M63 plus B. longum subsp. longum BB536). Severe neurodevelopmental impairment occurred in 7.4% of the single-strain group and 4.3% of the triple-strain group, a difference that was not statistically significant. Growth, BMI, and blood pressure were comparable [7].

Single-Strain Data Are Mixed

LGG is the most-studied single strain in neonatal medicine, and the results are not uniformly positive. A randomized controlled trial of 236 very low birth weight infants with gestational age ≤32 weeks gave LGG from feed initiation to 35 weeks corrected gestational age. The primary composite outcome of sepsis, NEC, or mortality occurred in 30.4% of the LGG group and 27.2% of controls, a relative risk of 0.85 with a confidence interval crossing 1.0. Mean time to full feeds and time to regain birth weight were nearly identical between groups [6].

That null result does not mean LGG is useless. It means this specific trial in this specific population did not detect the effect that earlier, smaller trials reported. That is a common pattern in neonatal probiotic research, and it is one reason international guidelines have been slow to recommend routine use.

The NEC Evidence Is Not the Same as the Sepsis Evidence

Probiotic supplementation reduces NEC more reliably than it reduces late-onset sepsis. The mechanism for this is plausible: NEC is a gut-local disease, while sepsis is systemic, and probiotics colonize the gut lumen. Nooral systemic coverage from an enteral probiotic is limited. One systematic review stated this explicitly, noting that several studies support a decrease in NEC incidence and, to a lesser extent, sepsis or late-onset sepsis [5].

Breastfeeding and the Newborn Gut

Breast milk and probiotics are not competing strategies. They work together. Breast milk provides human milk oligosaccharides that selectively feed Bifidobacterium, plus lactoferrin and immunoglobulins that inhibit pathogens. Probiotics add live organisms that compete for the same niche. A 2026 review proposes that short-chain fatty acids and tryptophan-derived indole metabolites are the proximal mediators linking this synergy to host protection [4].

Maternal Supplementation: What Actually Reaches the Infant

A common question is whether a breastfeeding probiotic taken by the mother changes the infant's gut. The best-designed study on this point used L. reuteri SGL 01 at 1 × 10⁹ CFU daily for 30 days in mothers of term, exclusively breastfed infants. Breast milk microbiota composition did not change for Bifidobacterium, Lactobacillus, Clostridium, or the Bacteroides fragilis group. However, neonatal fecal samples in the supplemented group showed significant increases in Bifidobacterium (p < 0.001), Lactobacillus (p = 0.029), and Clostridium (p = 0.003) at 30 days [12].

The interesting part is the dissociation. Maternal supplementation did not alter the milk, yet it altered the infant gut. The trial was small (27 dyads completed) and open-label, so it should be treated as hypothesis-generating. Still, it suggests that a breastfeeding probiotic may act through maternal gut transfer, skin contact, or another route that bypasses milk composition.

Infant Supplementation: Colonization Data

For direct infant supplementation, the cleanest dose-response data come from a 9-week randomized trial of B. infantis EVC001 in 2- to 4-month-old exclusively breastfed infants. Four groups received placebo, 4.0 × 10⁹, 8.0 × 10⁹, or 1.8 × 10¹⁰ CFU per day for 28 days. Fecal B. infantis levels were significantly higher in all supplemented groups at day 28 and day 63. The abundance of fecal Bifidobacteriaceae increased nearly 2-fold regardless of dose [11].

That study enrolled older infants (2 to 4 months), not newborns, and all doses produced similar colonization. The practical implication is that throwing a higher CFU number at the problem does not necessarily produce more colonization for this strain in this population.

The 2023 FDA Warning and the Safety Record

No probiotic product is FDA-approved as a drug. In the United States, probiotics are marketed as dietary supplements. That legal status has two consequences. First, products do not need to demonstrate efficacy before sale. Second, viability at the point of use is not guaranteed, because supplement manufacturing has less oversight than pharmaceutical manufacturing.

In 2023, the FDA issued warnings after a preterm infant death in the United States was linked to a probiotic product contaminated with a pathogen. Those actions triggered rapid changes in NICU practice. A natural experiment using the Pediatrix Clinical Data Warehouse compared high probiotic-use centers with low-use centers before and after the FDA action. In the high-use centers, probiotic use fell from 86% to 6.9%. In low-use centers, use fell from 13% to 0.1%. NEC incidence rose in high-use centers from 2.7% to 4.4% and remained essentially unchanged in low-use centers at 3.6%. The adjusted difference-in-differences was 1.18% (95% CI 0.03-2.33%, p = 0.045) [16].

That finding is the strongest available signal that these products were doing something clinically meaningful. When NICUs stopped using them quickly, NEC increased. The study design is observational, so it cannot prove causation, but the direction and timing are hard to dismiss.

What the Safety Concerns Mean for Parents and Clinicians

The FDA warnings did not resolve the underlying quality problem. Products still vary in strain identity, CFU count at expiry, and contamination risk. A 2025 review noted that routine use remains limited because of heterogeneity in NICU practices, uncertainty around optimal strains, dose, and duration, and insufficient long-term safety data [17]. Another review emphasized that inconsistent results due to strain differences and clinical heterogeneity limit widespread adoption, along with safety concerns in this vulnerable population [5].

For a preterm infant in the NICU, the decision to use a probiotic should be made by the neonatal team, using a product with published strain identity and verified CFU counts. For a healthy term infant at home, the risk calculation is different. Invasive infection from a contaminated probiotic is rare in immunocompetent term infants, but it is not zero, and the evidence of benefit is weaker.

Where Invasive Infection Risk Concentrates

The infants at highest risk of probiotic-associated infection are those with central venous catheters, compromised gut barriers, or severe immunodeficiency. The FDA warning specifically concerned preterm infants. A product that is safe for a healthy 6-month-old may not be safe for a 900-gram infant with a central line. This is why the population matters as much as the strain.

Jaundice and Other Neonatal Outcomes

Several trials have tested probiotics as adjuncts to phototherapy for neonatal hyperbilirubinemia. These are term or near-term populations, and the outcomes are different from NEC.

A randomized controlled trial of 44 neonates with pathological unconjugated hyperbilirubinemia compared phototherapy alone with phototherapy plus oral Bacillus clausii. Both groups had significant declines in total and indirect bilirubin, but only the probiotic group had a significant reduction in direct bilirubin. The probiotic group also had significantly greater reductions in lipopolysaccharide and tumor necrosis factor-α [13].

A retrospective cohort of 377 infants compared phototherapy alone with two probiotic regimens: Bifidobacterium quadruple viable tablets and a Bacillus subtilis plus Enterococcus faecium granule product. Both probiotic groups had shorter hospital stays and fewer adverse reactions than phototherapy alone. This was a non-randomized, unblinded study, so the results are weaker than an RCT [18].

A separate randomized trial tested the combination of a Lactobacillus rhamnosus product plus oral nystatin in 104 low birth weight neonates under 2500 grams. The intervention group had a lower frequency of positive C. albicans stool cultures at day 7 and shorter times to full feeding and discharge [14].

These are real findings, but they are adjunctive therapy for specific conditions, not general newborn supplementation. None of them justify giving a probiotic to a healthy term newborn who is feeding well and gaining weight.

Comparative Veterinary Note: Calf and Puppy Neonatal Diarrhea

The principles that govern probiotic use in human newborns apply to veterinary neonates, with one important difference: the evidence base is thinner and the regulatory pathway is different. In the United States, veterinary probiotic products are also marketed as supplements, not drugs, and strain identity and CFU counts at the point of use are not guaranteed by the FDA.

In calves, neonatal diarrhea is the leading cause of mortality in the first month of life, and the pathogens involved (Escherichia coli, Cryptosporidium, rotavirus, coronavirus) overlap with the dysbiosis patterns seen in preterm infants. Probiotic products for calves typically contain Lactobacillus, Bifidobacterium, Enterococcus, or Saccharomyces species, and they are often given in milk replacer or as an oral drench in the first 24 to 48 hours. The rationale is the same: compete with pathogens, support barrier function, and modulate inflammation. The evidence for any specific strain in calves is much weaker than for L. rhamnosus GG or the Bifidobacterium combinations in preterm infants, and products vary widely in quality.

In puppies, neonatal diarrhea in the first two weeks of life is a medical emergency. It is often caused by canine parvovirus, E. coli, Campylobacter, or Giardia, and it can kill a puppy within hours through dehydration and hypoglycemia. Probiotics are sometimes used as adjuncts during recovery, but they are not a treatment for the underlying infection. Any puppy with diarrhea in the first two weeks needs immediate veterinary assessment, not an over-the-counter supplement.

The key veterinary takeaway is that probiotics in neonatal animals are adjuncts at best. They do not replace fluid therapy, antimicrobials when indicated, or maternal colostrum, which is the single most important factor in neonatal immunity for both calves and puppies. If you are considering a probiotic for a neonatal animal, ask your veterinarian for a product with a named strain and a verified CFU count.

Practical Guidance for Parents

For Preterm Infants in the NICU

Do not start a probiotic on your own. The decision should be made by the neonatal team, and the product should have a named strain, a published CFU count, and verified viability. Ask which strain is being used, what dose, and for how long. The most-studied combinations are described in the table above.

For Term Infants at Home

The evidence for routine probiotic supplementation in healthy term newborns is weak. If your infant has colic, eczema, or feeding difficulty, discuss it with your pediatrician. Some trials show benefit for specific strains in specific conditions, and some do not. A breastfeeding probiotic taken by the mother may alter the infant gut, but the evidence is preliminary [12]. If you choose to use a product, look for a named strain, a stated CFU count, and a manufacturer that publishes third-party testing.

What to Avoid

Avoid products that list "probiotic blend" without strain names. Avoid products with no CFU count on the label. Avoid giving a probiotic to a preterm infant or an immunocompromised infant without direct medical supervision. Avoid using a probiotic to treat a sick newborn instead of seeking care.

Limitations and When to Contact a Veterinarian

This article is educational and is not a substitute for veterinary diagnosis or treatment. Individual cases need a veterinarian or pediatrician. The evidence base for probiotics in newborns is heterogeneous, and many products on the market have not been tested in the populations that use them.

Contact a veterinarian or pediatrician immediately if a newborn or neonatal animal shows any of the following:

• Bloody stools, black stools, or stools that look like currant jelly
• Vomiting that is green, bloody, or projectile
• A swollen, firm, or tender abdomen
• Refusal to feed, weak suck, or inability to latch
• Lethargy, poor responsiveness, or a temperature that is too low or too high
• Fewer wet diapers, sunken eyes, or other signs of dehydration
• Any new fever or signs of systemic illness after starting a probiotic

In neonatal animals, the threshold for calling a veterinarian is even lower. A puppy or calf with diarrhea in the first two weeks of life can deteriorate within hours. Do not wait to see if a probiotic helps.

Frequently Asked Questions

Are probiotics safe for newborns?

Safety depends on the infant and the product. Preterm infants in the NICU have a higher risk of invasive infection from contaminated products, which is why the FDA issued warnings in 2023 and why many NICUs changed their protocols [16]. Healthy term infants have a lower risk, but no probiotic product is FDA-approved as a drug, so quality varies.

Which probiotic strains have the best evidence in preterm infants?

Multi-strain Bifidobacterium and Lactobacillus combinations have the most consistent evidence for reducing NEC. Specific studied combinations include L. fermentum CECT5716 plus B. breve CECT7263 and the B. infantis Bb-02, B. lactis BB-12, and S. thermophilus TH-4 formulation [8][9]. Single-strain LGG has mixed results [6].

Do probiotics help with colic in term infants?

The evidence is strain-specific and weaker than for NEC prevention. Some trials show benefit for specific strains, and others do not. Discuss it with your pediatrician, and do not use a probiotic to replace standard care for a distressed infant.

Can a breastfeeding mother take a probiotic to help her baby?

Possibly. A small exploratory trial found that maternal L. reuteri SGL 01 at 1 × 10⁹ CFU daily for 30 days did not change breast milk microbiota but did increase Bifidobacterium, Lactobacillus, and Clostridium in neonatal feces [12]. The trial was small and open-label, so the finding needs confirmation.

What dose of probiotics should a newborn get?

There is no single dose. Doses in published trials range from 1 × 10⁶ CFU per strain per day for the low-dose L. fermentum plus B. breve combination up to 1.8 × 10¹⁰ CFU per day for B. infantis EVC001 in older breastfed infants [8][11]. Use the dose that matches the strain and population in the published trial, not a dose from a different product.

Are probiotics FDA-approved for newborns?

No. The FDA has not approved any probiotic product as a drug for newborns or any other population in the United States. Products are sold as dietary supplements, which means they do not need to prove efficacy before sale and viability at the point of use is not guaranteed.

What happened with the 2023 FDA warning?

The FDA issued warnings after a preterm infant death in the United States was linked to a contaminated probiotic product. A subsequent analysis found that when high-use NICUs stopped using probiotics, NEC incidence rose from 2.7% to 4.4%, while low-use centers showed no change [16].

Should I give my puppy or calf a probiotic for diarrhea?

Only under veterinary guidance. Neonatal diarrhea in puppies and calves can be fatal within hours, and probiotics are adjuncts at best. They do not replace fluid therapy, colostrum, or specific treatment for the underlying infection. Call a veterinarian first.

Related Articles

• Can Cats Eat Yogurt? Probiotic Gut Health Benefits
• Can Dogs Eat strawberries? Vet Safety, Benefits & Hazards
• Can Dogs Eat watermelon? Vet Safety, Benefits & Hazards
• Can Dogs Eat blueberries? Vet Safety, Benefits & Hazards
• Can Dogs Eat apples? Vet Safety, Benefits & Hazards
• Can Dogs Eat bananas? Vet Safety, Benefits & Hazards

Sources

1. Effect of Probiotic Supplementation in Preventing Necrotizing Enterocolitis Sepsis and Mortality Among Preterm and Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis.
2. Relationship between gut microbiota establishment patterns and the risk of necrotizing enterocolitis in preterm infants: a retrospective cohort study.
3. Necrotizing Enterocolitis in Preterm Infants: An Inflammatory Condition at the Crossroads of Intestinal Immaturity, Dysbiosis, and Nutrition.
4. Synergistic regulation of gut microbiota and metabolites by breast milk and probiotics in the prevention of neonatal necrotizing enterocolitis: mechanisms and prospects.
5. A Review of Probiotic Interventions for Necrotizing Enterocolitis and Sepsis in Preterm Infants.
6. Lactobacillus rhamnosus GG to Reduce Necrotising Enterocolitis, Sepsis, and Mortality in Very Low Birth Weight Infants: A Randomized Controlled Trial.
7. School-Age Neurodevelopmental and Atopy Outcomes in Extremely Preterm Infants: Follow-Up from the Single Versus Triple-Strain Bifidobacterium Randomized Controlled Trial.
8. L.Fermentum CECT5716 and B.Breve CECT7263 on premature infants morbidities: a randomized clinical trial.
9. Probiotic Implementation and Necrotizing Enterocolitis Risk in Preterm Infants.
10. A Randomized Controlled Trial of Probiotic Intervention for Reducing the Risk of Bronchopulmonary Dysplasia in Preterm Infants.
11. Randomized, placebo-controlled trial reveals the impact of dose and timing of Bifidobacterium infantis probiotic supplementation on breastfed infants' gut microbiome.
12. Effect of Supplementation with Lactobacillus reuteri SGL 01 in Lactating Women on Breast Milk and Neonatal Gut Microbiota: An Exploratory, Randomized, Open-Label Clinical Trial.
13. Efficacy of Bacillus clausii as an adjuvant therapy in pathological neonatal unconjugated hyperbilirubinemia in the Nile Delta region of Egypt: a randomized controlled trial.
14. Randomized controlled clinical trial of the impact of combined application of rhamnosus probiotics and oral nystatin on the colonization of intestinal Candida albicans in low birth weight neonates <2,500 grams.
15. Comparative effects of probiotics and pentoxifylline on intestinal injury biomarkers (HMGB-1, I-FABP) in preterm neonates with necrotizing enterocolitis: A randomized controlled trial.
16. Probiotics and necrotizing enterocolitis in preterm infants after the food and drug administration warning actions.
17. Probiotics in the fight against necrotizing enterocolitis: a cost-effective yet underutilized strategy in neonatal care.
18. Comparative effectiveness of different probiotics combined with phototherapy for neonatal hyperbilirubinemia: a retrospective, non-randomized cohort study.